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Abstract
Introduction: microRNA (miRNA) are short, noncoding RNA that negatively regulate gene expression and may play
a causal role in invasive breast cancer. Since many genetic aberrations of invasive disease are detectable in early
stages, we hypothesized that miRNA expression dysregulation and the predicted changes in gene expression
might also be found in early breast neoplasias.
Methods: Expression profiling of 365 miRNA by real-time quantitative polymerase chain reaction assay was
combined with laser capture microdissection to obtain an epithelium-specific miRNA expression signature of
normal breast epithelium from reduction mammoplasty (RM) (n = 9) and of paired samples of histologically normal
epithelium (HN) and ductal carcinoma in situ (DCIS) (n = 16). To determine how miRNA may control the expression
of codysregulated mRNA, we also performed gene expression microarray analysis in the same paired HN and DCIS
samples and integrated this with miRNA target prediction. We further validated several target pairs by modulating
the expression levels of miRNA in MCF7 cells and measured the expression of target mRNA and proteins.
Results: Thirty-five miRNA were aberrantly expressed between RM, HN and DCIS. Twenty-nine miRNA and
420 mRNA were aberrantly expressed between HN and DCIS. Combining these two data sets with miRNA target
prediction, we identified two established target pairs (miR-195:CCND1 and miR-21:NFIB) and tested several novel
miRNA:mRNA target pairs. Overexpression of the putative tumor suppressor miR-125b, which is underexpressed in
DCIS, repressed the expression of MEMO1, which is required for ErbB2-driven cell motility (also a target of miR-
125b), and NRIP1/RIP140, which modulates the transcriptional activity of the estrogen receptor. Knockdown of the
putative oncogenic miRNA miR-182 and miR-183, both highly overexpressed in DCIS, increased the expression of
chromobox homolog 7 (CBX7) (which regulates E-cadherin expression), DOK4, NMT2 and EGR1. Augmentation of
CBX7 by knockdown of miR-182 expression, in turn, positively regulated the expression of E-cadherin, a key protein
involved in maintaining normal epithelial cell morphology, which is commonly lost during neoplastic progression.
Conclusions: These data provide the first miRNA expression profile of normal breast epithelium and of preinvasive
breast carcinoma. Further, we demonstrate that altered miRNA expression can modulate gene expression changes
that characterize these early cancers. We conclude that miRNA dysregulation likely plays a substantial role in early
breast cancer development.
Introduction
Considerable molecular pathology research has focused
on invasive breast cancer (IBC); however, less attention
has been given to the preinvasive nonobligate precursor,
ductal carcinoma in situ (DCIS). DCIS is the fourth
most common cancer diagnosis among women and is
present in the vast majority of IBC cases [1]. Women
diagnosed with DCIS are at an increased risk of subse-
quently developing IBC, and, when examined, DCIS and
IBC also share many of the same genetic features. How-
ever, there is an increased need to better understand the
early genetic events and identify biomarkers that are
present prior to IBC. microRNA (miRNA) have emerged
as a new class of gene regulators that may serve as both
molecular biomarkers and novel therapeutic targets. In
this study, we sought to investigate miRNA expression
changes and their consequences in preinvasive breast
cancer.
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posttranscriptional control over their mRNA targets
through the mechanism of RNA interference. By com-
p l e m e n t a r yb i n d i n gt ot h e3 ’ untranslated region of tar-
get mRNA, miRNA promote mRNA destabilization,
thereby inducing translational repression [2]. It has been
demonstrated that miRNA control major cellular pro-
cesses, including metabolism, developmental timing,
stem cell division, cell growth and differentiation and
apoptosis [3-5]. Given this expansive role, it is unsur-
prising that their effect on mRNA expression contri-
butes to the pathogenesis of many diseases, including
cancer [6,7]. To date, more than 900 miRNA have been
identified in humans, constituting more than 1% of the
total coding genome. It is predicted that more than 60%
of mRNA may be targeted and that a single miRNA
may target as many as 200 mRNA, thus making miRNA
the largest class of gene regulators [8-10].
Several studies have established the role of miRNA in
the pathogenesis of IBC. For example, abnormal miRNA
expression has been described in breast cancer cell lines
and in bulk primary normal and cancerous breast tissues
[11-13]. In this setting, miRNA expression has corre-
lated with specific breast cancer biopathologic features,
such as estrogen receptor (ER) and progesterone recep-
tor (PR) expression, tumor stage, vascular invasion or
proliferation index. In addition, many miRNA that are
consistently downregulatedm a ya c ta st u m o rs u p p r e s -
sors, for example, miR-206, miR-17-5p, miR-125a,
miR-125b and the let-7 family, and many that are con-
sistently upregulated may acts as oncogenes, for exam-
ple, miR-21, miR-10b and miR-27a. Other studies have
shown that miRNA exhibit a specific spatial distribution
of expression within breast epithelium [14].
Almost all human breast cancers arise in the epithelial
compartment, likely as a result of the transformation of
epithelial cells, although the surrounding stroma and
microenvironment play a crucial role in tumor progres-
sion. Therefore, the present work is focused on the
genetic changes that occur within the epithelial cell
population.
We hypothesized that miRNA expression might be dys-
regulated prior to IBC, that these changes might be asso-
ciated with mRNA expression changes and that together
these might help to elucidate important steps in early
breast tumorigenesis. Therefore, to first obtain a profile
of normal miRNA expression, we profiled miRNA in nor-
mal epithelium from healthy controls undergoing reduc-
tion mammoplasty (RM). Next, to obtain a profile of
miRNA dysregulated prior to invasion, we examined
miRNA expression in histologically normal (HN) epithe-
l i u ma n dc o m p a r e dt h i st op a i r e ds a m p l e so fa d j a c e n t
DCIS. We then integrated the HN:DCIS miRNA expres-
sion profile with the gene expression profile from the
same samples and used miRNA target prediction pro-
grams to identify putative miRNA:mRNA functional
interactions. We then selected three candidate miRNA
(miR-125b, miR-182 and miR-183) and six of their puta-
tive target genes (MEMO1, NRIP1, CBX7, DOK4, NMT2,
and EGR1) for validation. This study represents the first
report of a miRNA expression profile in normal breast
epithelium and the first integrated analysis of dysregu-
lated miRNA and mRNA expression in paired HN and
DCIS samples. Many of the dysregulated miRNA identi-
fied in DCIS have previously been identified in IBC. Our
data suggest an important role for miRNA in determin-
ing the parallel gene expression changes that characterize
the earliest stage of breast disease.
Materials and methods
Tissue sample acquisition and preparation
Primary breast tissues not needed for diagnosis were
obtained at Boston Medical Center from patients under-
going RM and breast cancer surgery (prior to any
chemo- or radiation therapy). All samples were deidenti-
fied and assigned a number at the time of collection;
therefore, informed consent was not required according
to our specimen collection protocol preapproved by the
Boston University Medical Center Institutional Review
Board. Samples were processed as described previously
[15]. Epithelia from three groups were examined: normal
breast tissue (n = 9) from RM (mean age, 52.2 years; age
range, 44 to 75 years) and paired samples of HN and
DCIS (n = 16) from eight individuals undergoing cancer
surgery. Hematoxylin and eosin-stained sections were
reviewed by a pathologist (AdlM) to verify normal
epithelia and preinvasive lesions.
Laser capture microdissection and RNA isolation
Laser capture microdissection (LCM) was performed as
described previously [15-17] to collect breast epithelial
cells of normal appearing ductal tissue (RM and HN)
and epithelial cells of identified regions of DCIS. Total
RNA was isolated using the RNAqueous miRNA Isola-
tion Kit (Ambion, Austin, TX, USA) and treated with
DNase I according to the manufacturer’si n s t r u c t i o n s .
RNA to be utilized for gene expression analysis was pro-
cessed as described previously [15,16]. The pooled RM
sample was prepared by combining 400 ng of total RNA
from each of the nine RM samples.
miRNA expression profiling and statistical analysis
cDNA was synthesized from 800 ng (100 ng/multiplex
pool) with the TaqMan miRNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA), accord-
ing to manufacturer’s instructions. miRNA expression
was measured by real-time quantitative polymerase
chain reaction (RT-qPCR) assay utilizing the TaqMan
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Base version 9.2; Applied Biosystems) and assayed on
the 7900 Real-Time PCR System (Applied Biosystems),
according to the manufacturer’s instructions. miRNA
expression data are available from the National Center
for Biotechnology Gene Expression Omnibus (GEO)
[18] at accession number [GEO:GSE24509].
All probes with threshold cycles (Ct) = 40 in more than
two of three pooled RM (PRM) replicates or more than
six of eight HN samples and more than six of eight DCIS
samples were considered “nonexpressed” and removed.
Remaining Ct values were global median normalized by
transforming all expression values by rescaling to a target
value of 12 (ΔCt). Relative changes in miRNA expression
among each comparison (HN-PRM, DCIS-PRM and
DCIS-HN) were assessed (ΔΔCt ). A variance correction
was applied to account for the pooled samples as sug-
gested by Churchill [19], and a t-test was performed. P <
0.005 in at least one of the comparisons was considered
statistically significant. To address the issue of multiple
comparisons, we highlight the results that remain signifi-
cant using two valid procedures: the more restrictive
Bonferroni correction (P < 0.00025) and the less restric-
tive false discovery rate < 0.05 (P < 0.017), which typically
results in a greater number of significant results. The
relative fold change for each comparison was calculated
by 2^
-ΔΔCt. Heatmaps were generated using the Heatplus
package in Bioconductor [20].
Gene expression profiling and statistical analysis
Gene expression analysis was measured on the U133A
GeneChip (Affymetrix, Santa Clara, CA, USA). All
microarray analyses were performed at the Boston
U n i v e r s i t yM i c r o a r r a yF a c i l i t ya sp r e v i o u s l yd e s c r i b e d
[15]. The paired data were assembled as follows: 12
paired samples (six HN and six DCIS) were pulled from
the data published by Emery et al. [15], two HN samples
were pulled from the data published by Graham et al.
[21], and the two matching pairs of DCIS samples (com-
bined to equal 16 paired samples) were collected and
p r o c e s s e df r o mt i s s u ea c q u i r e df r o mt h es a m ep a t i e n t .
A r r a yd a t aw e r ea n a l y z e da sp r e v i o u s l yd e s c r i b e d[ 1 5 ] .
Microarray output data were filtered by removing all
probe sets present in < 15% of all samples. Next, data
were analyzed by performing Bayesian Analysis of Dif-
ferential Gene Expression (BADGE) as previously
described by Emery et al. [15] and found online at the
BADGE website [22]. The gene expression data are
available from GEO under accession number [GEO:
GSE24509].
miRNA target prediction
SigTerms [23] was utilized to extract predictions from
PicTar [24], TargetScan (4.1 and 5.1) [25] and miRanda
(Jan 08 and Sep 08) [26]. miRNA target predictions
were extracted two separate times, the first using Tar-
getScan release 4.1 and miRanda release Jan 08 and the
second using TargetScan release 5.1 and miRanda
release Sep 08. The final prediction results are a combi-
nation of the two queries. Pearson correlations and
associated P values were calculated across all 16 HN
and DCIS samples for each of the target pairs identified
from the intersection of the programs.
Gene ontology and pathway analysis
Gene annotation, ontology and pathway analysis were
conducted using the Database for Annotation, Visualiza-
tion and Integrated Discovery [27]. A modified Fisher’s
exact test/EASE (Enrichment) Score was utilized to cal-
culate the P-values.
miRNA pre-miR and anti-miR transient transfection
MCF7 cells were kindly provided by G. Sonenshein
(Tufts-New England Medical Center, Boston, MA, USA)
and were maintained in Dulbecco’s modified Eagle’s
medium (Invitrogen, Carlsbad, CA, USA) with 4.5 g/l
glucose and sodium pyruvate supplemented with 5.8 g/l
L-glutamine (Cellgro, Manassas, VA, USA), 10% fetal
bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and
1% penicillin-streptomycin (Cellgro). For all experi-
ments, 5 × 10
4 cells/well of a 12-well plate were seeded
for 24 hours and then transfected with (1) 100 nM pre-
miR-125b or scrambled negative control sequence
(Scramble) or (2) 50 nM Anti-miR-182, Anti-miR-183
or Scramble using the siPORT NeoFX Transfection
Agent (Ambion).
RNA extraction cell culture
Cells were rinsed with 1× phosphate-buffered saline
(PBS) and lysed with 600 μl of lysis buffer, and total
RNA was isolated with the mirVana Isolation Kit
(Ambion) and treated with DNase I, according to the
manufacturer’s instructions. RNA quantity was deter-
mined using Quant-it RiboGreen RNA Quantitation
Reagent (Invitrogen) according to the manufacturer’s
instructions.
qRT-PCR for target gene expression
cDNA from 500 ng of total RNA was synthesized using
TaqMan RT reagents according to the manufacturer’s
instructions. qRT-PCR was performed by diluting RT pro-
duct in 2× Universal PCR MasterMix and 20× TaqMan
Gene Expression Assay for each gene to be measured:
chromobox homolog 7 (CBX7) (Hs00980916_g1), docking
protein 4 (DOK4) (Hs00902919_g1), early growth response
1( EGR1) (Hs00152928_m1), glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (4333764F), mediator of ErbB2-
driven cell motility (MEMO1) (Hs00831646_uH), N-
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nuclear receptor-interacting protein 1 (NRIP1/RIP140)
(Hs00942766_s1). PCR reactions were run on the 7500
real-time PCR instrument under the following conditions:
hold at 95°C for 10 minutes, then 40 cycles of 95°C for 15
seconds and 60°C for 1 minute. All reagents were pur-
chased from Applied Biosystems. Relative gene expression
was assessed using the differences in normalized Ct
(ΔΔCt) method after normalization to GAPDH. Fold
changes were calculated by 2^
-ΔΔCt.
Immunoblot analysis
Cells were washed with 1× PBS 48 hours posttransfec-
tion and collected in radioimmunoprecipitation assay
buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1%
NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate). Protein (50 μg) was electrophoresed through a
4% to 15% Tris·HCl Ready Gel (Bio-Rad, Hercules, CA,
USA) under reducing conditions and transferred onto a
polyvinylidene fluoride membrane. The membrane was
incubated with primary antibodies against CBX7
(ab21873; Abcam, Cambridge, MA, USA), E-cadherin
(610181; BD Biosciences, San Jose, CA, USA) and b-
actin (A5441; Sigma-Aldrich). Immune complexes were
detected using horseradish peroxidase-conjugated sec-
ondary antibodies and the SuperSignal West Pico Che-
miluminescent Substrate Kit (Pierce Biotechnology,
Rockford, IL, USA).
Results
miRNA expression profiles of RM, HN and paired DCIS
Our first goal was to generate a set of miRNA expres-
sion profiles in primary human healthy and diseased
breast epithelia. Therefore, we microdissected 25 sam-
ples to enrich for epithelial RNA from 17 patients (see
Additional file 1 for representative epithelial lesions)
separated into three groups: the control group of normal
epithelia from nine patients undergoing RM and the
paired diseased groups, which consisted of 16 samples
from eight patients (eight samples of HN and eight sam-
ples of adjacent ER- and PR-positive DCIS (Table 1).
Next, to test the reproducibility of the miRNA expres-
sion array, we combined equal amounts of RNA from
nine RM samples into a pooled RM (PRM). The PRM
served both as a heterogeneous biological control and as
a technical replicate. The PRM was run in triplicate and
showed a high correlation between each replicate with a
mean Pearson’s correlation of 0.95 (Additional file 2).
miRNA are differentially expressed in normal and
preinvasive breast cancer
By comparing the miRNA expression profiles between
PRM, HN and DCIS (see Additional file 3 for a list of
miRNA expressed in each group), we found that
35 miRNA were differentially expressed (P < 0.005) in at
least one comparison (see heatmaps in Figure 1A and
Additional file 4, as well as data in Table 2). As
expected, the fewest differences were found in the HN-
PRM comparison, where 11 miRNA were different
(seven overexpressed and four underexpressed). More
than twice that number were different in both the
DCIS-PRM and DCIS-HN comparisons, with 29 miRNA
being different and 23 of 29 overlapping between these
comparisons. In the DCIS-PRM comparison, 17 miRNA
were overexpressed and 12 were underexpressed; in the
DCIS-HN comparison, 15 miRNA were overexpressed
and 14 were underexpressed. It has been noted that
m i R N At h a ta r ep r e s e n tw i t h i n5 0k ba tt h es a m e
genetic loci are often coordinately expressed [28]. We
examined these 35 miRNA for coordinate expression
because of their close genomic proximity. The
35 miRNA were located at 29 different loci, and 16 of
35 miRNA were clustered at seven distinct loci (indi-
cated in Additional file 4). As expected, 14 (88%) of
16 miRNA < 13 kb apart were positively correlated, with
the exception of miR-17-3p and miR-18a.
Table 1 Paired histologically normal and DCIS sample summary
a
Sample Age, yr DCIS grade DCIS histology ER/PR/HER2 of IDC IDC grade
379 43 2 and 3 Cribiform +/+/+ 2
444 48 2 Cribiform +/+/NA Not present
248 49 1 Micropapillary +/+/NA 2
274 49 2 Solid +/+/- 1
380 53 2 and 3 Solid/cribiform +/+/- 2
446B 54 3 Comedo/solid +/+/- 2
258 65 1 and 2 Cribiform/micropapillary +/+/- 2
405 67 2 Micropapillary/cribiform +/+/- 2
Mean age 53.5
Median age 51.0
aDCIS, ductal carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal
carcinoma in situ; NA, not applicable.
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ture to determine whether any of these miRNA
are implicated in IBC. Twenty (57%) of the 35 miRNA
have previously been implicated (noted in Table 2)
[13,14,18,29-41]. Eleven of these 20 miRNA were over-
e x p r e s s e di nD C I Sc o m p a r e dt oH Na n dP R M( m i R -
181b, miR-200b, miR-200c, miR-18a, miR-21, miR-365,
miR-7, miR-182, miR-191, miR-193b and miR-93). The
directional change in expression in DCIS of seven (64%)
of these 11 miRNA is consistent with their reported
expression in IBC; the exceptions are miR-18a, miR-
193b, miR-200b and miR-200c. Nine of these 20 miRNA
were underexpressed in DCIS compared to HN and
PRM (let-7c, miR-10b [14], miR-125b, miR-127, miR-
145, miR-17-3p, miR-195, miR-204 and miR-383), and
the directional change in expression in DCIS of eight
(89%) of these nine miRNA is consistent with their
expression in IBC (except miR-195). Overall, 15 (75%)
of 20 miRNA that are dysregulated are concordantly
dysregulated in IBC. Of the 29 miRNA dysregulated in
DCIS compared to HN, 18 (62%) of 29 are implicated
in IBC and concordant with the reported changes in
expression.
Differentially expressed miRNA are predicted to target
differentially expressed genes in HN-DCIS comparison
The identification of miRNA targets is crucial to under-
standing the biological role of miRNA. We have recently
shown that gene expression is altered in paired HN and
DCIS epithelial cells [15]. Because mRNA destabilization
Figure 1 Expression profiling and target prediction of microRNA (miRNA) and genes in histologically normal (HN) and ductal
carcinoma in situ (DCIS). (A) and (B) Hierarchical clustering heatmaps of (A) miRNA (P < 0.005, fold change >3) and (B) mRNA (P < 0.05, fold
change >1.5) overexpressed (red) and underexpressed (green) in DCIS versus paired HN. Brackets indicate the most significant miRNA and probe
sets. Rows, transcripts/miRNA; columns, profiled patient samples; shaded boxes, lesion type. (C) Venn diagram depicting number of predicted
functional pairs for each miRNA target prediction algorithm (PicTar, TargetScan and miRANDA) and the intersection of algorithms, first and
second queries are separated by a forward slash.
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[39], we sought to determine whether any of the
29 miRNA altered in the HN-DCIS comparison may parti-
cipate in the regulation of these differentially expressed
genes through this mechanism. First, we examined the
gene expression profile from the same 16 paired HN and
DCIS samples. Data were analyzed by BADGE. BADGE
uses a model-averaging approach to calculate the posterior
probability of a fold change > 1 for each probe set and
ranks the genes, so that probe sets with a very small prob-
ability (< 0.025) or a very large one (> 0.975) are
considered differentially expressed. On the basis of the
BADGE analysis, we selected the probe sets in which the
probability of a fold change > 1.5 was either > 0.975 or <
0.025. These probe sets were further analyzed using a lin-
ear mixed model with lognormal errors and random
effects to account for patient matching across probe sets.
On the basis of this analysis, we obtained a set of 497
probe sets (420 genes) that were differentially expressed (P
< 0.05, fold change > 1.5) between HN and DCIS, 208
probe sets (181 genes) that were overexpressed and 289
probe sets (239 genes) that were underexpressed (Figure
Table 2 Differentially expressed microRNA among pooled reduction mammoplasty, histologically normal and ductal
carcinoma in situ
a
HN versus PRM DCIS versus PRM DCIS versus HN
microRNA Fold change P value
b Fold change P value
b Fold change P value
b
let-7c [62] 15.23 3.46E-03
c 0.31 1.25E-01 0.03 1.19E-03
c
miR-7 [38] 3.12 1.35E-01 22.35 1.53E-03
c 5.19 4.92E-02
miR-10b [13,39] 2.90 1.59E-01 0.82 7.82E-01 0.04 2.58E-03
c
miR-17-3p [32,40] 19.04 2.14E-03
c 2.20 2.85E-01 0.12 1.73E-02
miR-18a [34] 1.91 3.76E-01 20.88 1.76E-03
c 3.53 1.12E-01
miR-21 [13,31,36,40,41] 6.74 2.23E-02 55.20 2.64E-04
c 20.92 3.21E-03
c
miR-93[34] 7.53 1.72E-02 193.86 3.33E-05d 160.47 1.59E-04d
miR-99a 1.90 3.79E-01 0.53 3.79E-01 0.02 9.19E-04
c
miR-99b 3.08 1.39E-01 14.84 3.66E-03
c 6.24 3.33E-02
miR-125b [13,29] 0.93 9.24E-01 0.08 5.39E-03
c 0.05 4.03E-03
c
miR-127 [30,31] 1.77 4.30E-01 0.25 7.81E-02 0.02 5.30E-04
c
miR-130a 0.29 1.06E-01 0.01 1.38E-04
d 0.09 1.01E-02
miR-145 [13,14] 3.00 1.47E-01 0.80 7.52E-01 0.03 1.20E-03
c
miR-181b [31,40] 3.40 1.11E-01 14.90 3.64E-03
c 5.46 4.42E-02
miR-182 [33] 2.00 3.45E-01 106.24 8.54E-05
d 72.35 4.55E-04
c
miR-183 2.52 2.15E-01 19.06 2.14E-03
c 51.88 7.38E-04
c
miR-191 [13] 6.75 2.23E-02 78.21 1.43E-04
d 31.59 1.60E-03
c
miR-193b [18] 2.20 2.84E-01 15.67 3.25E-03
c 6.87 2.73E-02
miR-195 [35] 1.37 6.57E-01 0.06 2.78E-03
c 0.13 2.15E-02
miR-200b [37] 1.70 4.63E-01 6.07 2.86E-02 51.31 7.50E-04
c
miR-200c [37] 1.90 3.80E-01 26.41 1.08E-03
c 19.98 3.48E-03
c
miR-204 [13] 0.77 7.12E-01 0.04 1.32E-03
c 0.08 8.12E-03
c
miR-324-5p 2.86 1.64E-01 24.38 1.28E-03
c 92.53 3.24E-04
c
miR-365 [31] 4.05 7.45E-02 17.65 2.51E-03
c 25.05 2.35E-03
c
miR-376a 0.45 2.73E-01 0.06 3.14E-03
c 0.24 7.91E-02
c
miR-382 2.03 3.32E-01 0.11 1.20E-02
c 0.06 4.71E-03
c
miR-383 [34] 0.05 2.15E-03
c 0.01 1.58E-04
d 0.62 5.18E-01
miR-410 0.96 9.56E-01 0.15 2.33E-02
c 0.00 1.11E-04
d
miR-425-5p 1.38 6.57E-01 9.47 1.01E-02
c 74.46 4.37E-04
c
miR-449a 10.65 7.71E-03
c 15.12 3.52E-03
c 2.53 2.23E-01
miR-449b 0.79 7.37E-01 11.57 6.39E-03
c 21.20 3.13E-03
c
miR-486 0.02 2.06E-04
d 0.01 9.73E-05
d 0.34 1.65E-01
miR-489 0.06 2.73E-03
c 0.10 8.61E-03
c 0.25 8.62E-02
miR-511 0.40 2.20E-01 0.07 3.72E-03
c 0.18 4.11E-02
miR-517
c 0.07 3.48E-03
c 0.01 1.29E-04
d 0.36 1.82E-01
aRM, reduction mammoplasty; PRM, pooled reduction mammoplasty; HN, histologically normal; DCIS, ductal carcinoma in situ; microRNA in boldface type have
previously been implicated in invasive breast cancer;
bP value determined by Student’s t-test;
cP < 1.7E-02 implies significance with a false-discovery rate of 0.05;
dP < 2.5E-04 implies significance after the Bonferroni correction; fold change in expression between comparisons was considered significant if P < 5E-02.
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a
microRNA
expression
Gene expression miRNA:mRNA
miRNA Fold
change
Probe ID Gene symbols, gene names Fold
change
Expression
correlation
P value
b
let-7
c 0.03 203481_at C10ORF6, chromosome 10 open reading frame 6 1.58 -0.58 1.88E-02
218567_x_at DPP3, dipeptidylpeptidase 3 2.31 -0.49 5.4E-02
203358_s_at EZH2, enhancer of zeste homolog 2 (Drosophila) 2.36 -0.64 7.69E-03
209283_at SLC20A1, solute carrier family 20 (phosphate transporter),
member 1
2.06 -0.30 2.53E-01
203358_s_at TRIB1, tribbles homolog 1 (Drosophila) 1.77 -0.48 5.84E-02
miR-10b 0.04 202357_s_at SDC1, syndecan 1 2.06 -0.28 2.96E-01
miR-125b 0.05 203744_at HMGB3, high-mobility group box 3 2.13 -0.61 1.27E-02
209613_s_at NRIP1, nuclear receptor interacting protein 1 2.25 -0.39 1.36E-01
213004_at MEMO1, mediator of cell motility 1 1.73 -0.59 1.54E-02
miR-17-3p 0.12 203744_at HMGB3, high-mobility group box 3 2.13 -0.49 5.66E-02
212446_s_at LASS6, LAG1 longevity assurance homolog 6 1.78 -0.31 2.38E-01
211653_x_at MAP7, microtubule-associated protein 7 1.73 -0.49 5.19E-02
213492_at SERP1, stress-associated endoplasmic reticulum protein 1 1.80 -0.23 3.84E-01
203213_at SAR1B, SAR1 gene homolog B (Saccharomyces cerevisiae) 1.95 -0.07 8.03E-01
202381_at ADAM9, ADAM metallopeptidase domain 9 2.04 -0.45 7.89E-02
miR-181b 5.46 221234_s_at BACH2, BTB and CNC homology 1 basic leucine zipper
transcription factor 2
0.47 -0.30 2.62E-01
212914_at CBX7, chromobox homolog 7 0.44 -0.30 2.67E-01
204753_s_at
204755_x_at
204754_at
HLF, hepatic leukemia factor 0.24
0.28
0.31
-0.19
-0.52
-0.45
4.84E-01
3.82E-02
7.70E-02
204567_s_at NMT2, N-myristoyltransferase 2 0.58 -0.35 1.81E-01
202274_at
200974_at
NR3C1, nuclear receptor subfamily 3, group C, member 1
(glucocorticoid receptor)
0.46
0.57
-0.44
-0.57
8.86E-02
2.21E-02
miR-182 72.35 221234_s_at BACH2, BTB and CNC homology 1 basic leucine zipper
transcription factor 2
0.47 -0.73 1.41E-03
210347_s_at
219497_s_at
219498_s_at
BCL11A, B-cell CLL/lymphoma 11A 0.27
0.42
0.43
-0.65
-0.69
-0.80
6.31E-03
2.86E-03
2.19E-04
221530_s_at BHLHB3, basic helix-loop-helix domain containing, class B, 3 0.47 -0.55 2.71E-02
204851_s_at
204850_s_at
DCX, doublecortex; lissencephaly, X-linked (doublecortin) 0.13
0.30
-0.83
-0.67
7.48E-05
4.63E-03
209691_s_at DOK4, docking protein 4 0.56 -0.53 3.65E-02
209905_at
214651_s_at
HOXA9, homeobox A9 0.10
0.31
-0.64
-0.55
8.18E-03
2.63E-02
64900_at LPHN2, latrophilin 2 0.37 -0.62 9.87E-03
219497_s_at PRKD1, protein kinase D1 0.54 -0.59 1.61E-02
210735_s_at RIMS3, regulating synaptic membrane exocytosis 3 0.52 -0.73 1.25E-03
205022_s_at FOXN3, checkpoint repressor 1 0.50 -0.67 4.40E-03
221935_s_at NCAM1, neural cell adhesion molecule 1 0.43 -0.41 1.19E-01
212914_at CBX7, chromobox homolog 7 0.44 -0.57 2.22E-02
204567_s_at NMT2, N-myristoyltransferase 2 0.58 -0.26 3.26E-01
miR-183 51.88 221234_s_at BACH2, BTB and CNC homology 1 basic leucine zipper
transcription factor 2
0.47 -0.75 7.83E-04
204851_s_at
204850_s_at
DCX, doublecortex; lissencephaly, X-linked (doublecortin) 0.13
0.30
-0.82
-0.80
1.06E-04
2.16E-04
201693_s_at EGR1, early growth response 1 0.45 -0.61 1.12E-02
202274_at
200974_at
NR3C1, nuclear receptor subfamily 3, group C, member 1
(glucocorticoid receptor)
0.46
0.57
-0.70
-0.45
2.77E-03
8.08E-02
miR-195 0.13 217852_s_at ARL8B, ADP ribosylation factor-like 8B 1.64 -0.31 2.49E-01
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provided in Additional file 5.
We then combined the two expression profiles to
identify putative miRNA:mRNA functional pairs linking
these 420 mRNA and 29 miRNA. To increase specificity
(at the cost of lower sensitivity), we integrated results of
three target prediction programs and examined only the
intersection. We found that 113 unique miRNA:mRNA
target pairs were predicted by all three programs, com-
posed of 74 genes and 13 miRNA (Figure 1C).
Returning to the expression data, we found that 59 of
113 miRNA:mRNA pairs (45 mRNA and 12 miRNA)
were inversely expressed and that 54 of 113 miRNA:
mRNA pairs (46 mRNA and 13 miRNA) were coordi-
nately expressed. The inverse pairs are the canonical
understanding of miRNA:mRNA interactions, meaning
that as the expression of one changes, it is expected that
the expression of the other will change in the opposite
direction. The coordinately expressed pairs can repre-
sent either false-positive predictions or positive target
regulation. The degree of anticorrelation for the inverse
pairs was calculated, and the results are listed in
Table 3. Similarly, the degree of correlation for the
coordinate pairs was calculated, and the data are pro-
vided in Additional file 6.
Gene ontology and pathway analysis of gene targets
reveals enriched involvement in transcription
To determine whether a particular molecular or biologi-
cal function or pathway was overrepresented among the
74 predicted target genes, we conducted gene ontology
and pathway analysis. According to these results, 23
( 3 1 % )o f7 4o ft h eg e n e sr e g u l a t et r a n s c r i p t i o n .O ft h e
23, 15 have transcription factor activity, four are tran-
scriptional repressors and nine are sequence-specific
DNA-binding factors (see Additional file 7). For exam-
ple, EGR1 and homeobox A9 (HOXA9)a r ep r e d i c t e d
targets (miR-183:EGR1 and let-7c/miR-182:HOXA9) and
are both transcription factors that regulate many genes,
including eukaryotic translation initiation factor 4E
(EIF4E), collagen type II, a1( COL2A1), NAB1 and
SNAIL (by EGR1), as well as EIF4E and MEIS2 (by
HOXA9). Interestingly, these genes were also differen-
tially expressed in the HN-DCIS comparison, and
Table 3 Expression correlation of microRNA and inversely expressed predicted targets
a (Continued)
208712_at CCND1, cyclin D1 [43] 2.30 -0.33 2.19E-01
208653_s_at CD164, CD164 molecule, sialomucin 2.40 -0.54 3.16E-02
202596_at ENSA, endosulfine a 2.03 -0.37 1.54E-01
211653_x_at MAP7, microtubule-associated protein 7 1.73 -0.52 4.00E-02
221935_s_at RAD23B, RAD23 homolog B 1.79 -0.08 7.61E-01
201341_at TMEM33, transmembrane protein 33 1.62 -0.30 2.64E-01
212464_s_at
216442_x_at
WWP1, WW domain containing E3 ubiquitin protein ligase 1 2.79
2.83
-0.49
-0.25
5.57E-02
5.57E-02
miR-204 0.08 217852_s_at ARL8B, ADP-ribosylation factor-like 8B 1.64 -0.27 3.06E-01
213492_at SERP1, stress-associated endoplasmic reticulum protein 1 1.80 -0.57 2.22E-02
miR-21 20.92 218992_at
219060_at
NFIB, nuclear factor I/B [42] 0.43
0.52
-0.75
-0.69
9.15E-04
3.28E-03
miR-7 5.19 213492_at COL2A1, collagen type II, a1 0.51 -0.12 6.61E-01
204359_at FLRT2, fibronectin leucine-rich transmembrane protein 2 0.35 -0.49 5.36E-02
206765_at KCNJ2, potassium inwardly rectifying channel, subfamily J,
member 2
0.33 -0.73 1.35E-03
214112_s_at SNCA, synuclein a 0.48 -0.54 3.00E-02
205022_s_at FOXN3, checkpoint repressor 1 0.50 -0.61 1.22E-02
miR-93 160.47 210347_s_at
219497_s_at
219498_s_at
BCL11A, B-cell CLL/lymphoma 11A 0.27
0.42
0.43
-0.75
-0.72
-0.71
7.40E-04
1.51E-03
2.11E-03
204753_s_at
204755_x_at
204754_at
HLF, hepatic leukemia factor 0.24
0.28
0.31
-0.68
-0.81
-0.81
3.60E-03
1.44E-04
1.49E-04
218992_at
219060_at
NFIB, nuclear factor I/B 0.43
0.52
-0.74
-0.65
1.14E-03
6.30E-03
203963_at RGL1, ral guanine nucleotide dissociation stimulator-like 1 0.53 -0.58 1.79E-02
204422_s_at
205117_at
TXNIP, thioredoxin-interacting protein 0.36
0.49
-0.69
-0.57
2.96E-03
2.14E-02
amiRNA, microRNA; miRNA:target mRNA pairs tested in this study are indicated by boldface type, and previously confirmed targets from the literature are
indicated by boldface italicized type,
bP value determined by Student’s t-test.
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COL2A1, let-7c:NAB1 and let-7c:MEIS2). Because of the
use of such a small gene list, no pathways reached a
level of significance (see Additional file 8); however, we
noted that several genes are associated with cancer-
related pathways, such as cell cycle regulation (cyclin D1
(CCND1)a n dYWHAZ), mitogen-activated protein
kinase (MAPK) signaling (fibroblast growth factor 2
(FGF2)a n dDOK4), nucleotide excision repair (RAD23
homolog B (RAD23B)) and p53 interactions (CCND1,
CBX7, enhancer of zeste homolog 2 (Drosophila)
(EZH2), WW domain containing E3 ubiquitin protein
ligase 1 (WWP1) and PTB4A1).
miR-125b, miR-182 and miR-183 target validation
Two of the 59 inverse miRNA:mRNA target pairs we
identified have been validated: miR-21:NFIB (an onco-
genic interaction) in leukemia cells [42] and miR-195:
CCND1 (a tumor-suppressive interaction) in hepatocel-
lular carcinoma [43]. Our data suggest a new role for
these proven interactions in DCIS.
We wished to validate additional miRNA:mRNA
inverse target pairs. On the basis of a high degree of dif-
ferential expression in DCIS, multiple predicted targets
and potential relevance to cancer, we selected six of 59
inverse target pairs consisting of three miRNA (miR-
125b, miR-182 and miR-183) for experimental manipu-
lation in a breast cancer cell line.
miR-125b expression is greatly reduced in DCIS com-
pared to HN (0.05-fold) and PRM (0.08-fold). Target
prediction analysis identified three inverse putative miR-
125b targets (Table 3). We selected MEMO1 and NRIP1
for validation. MEMO1 is a nonheme iron-dependent
dioxygenase that binds to the C-terminus of ErbB2/
Her2 (also a known target of miR-125b) and is required
for ErbB2-driven cell motility [29,44]. NRIP1/RIP140 is a
nuclear protein that modulates the transcriptional activ-
ity of the ER [45].
Figure 2 Effect of miR-125b overexpression and miR-182 and miR-183 knockdown on predicted target gene expression. (A) Reduced
average relative fold change in expression of predicted miR-125b targets: mediator of ErbB2-driven cell motility 1 (MEMO1)( * P < 0.08) and
nuclear receptor interacting protein 1 (NRIP1(RIP140))( * P < 0.05). (B) Increased average relative fold change in expression of predicted miR-182
targets: chromobox homolog 7 (CBX7), docking protein 4 (DOK4) and N-myristoyltransferase 2 (NMT2) and miR-183 target early growth response
1( EGR1)( * P < 0.05 and **P < 0.02). Target mRNA expression was measured at 24, 48 and 72 hours posttransfection (n = 4, all conditions).
Significant differences were determined by Student’s t-test. Error bars indicate standard error of the mean.
Figure 3 Effect of miR-182 on chromobox homolog 7 (CBX7)
and E-cadherin expression. (A) Protein levels of CBX7 and E-
cadherin after transfection with anti-miR-182 or scramble. b-actin
served as a loading control. (B) The percentage changes in levels of
CBX7 and E-cadherin were quantitated and normalized for b-actin.
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authentic miR-125b targets, we transiently expressed the
precursor of miR-125b in MCF7 cells. This reduced the
endogenous expression of MEMO1 as early as 24 hours
(0.75-fold), and expression was significantly further
decreased at 48 hours (0.62-fold) and remained below
baseline at 72 hours (0.84-fold). Similarly, the expression
of NRIP1 was reduced at 24 hours (0.63-fold), and
expression was significantly further decreased at 48
hours (0.53-fold) and remained below baseline at 72
hours (0.68-fold) (Figure 2A). These results suggest that
both MEMO1 and NRIP1 are negatively regulated by
miR-125b.
miR-182 and miR-183 expression is greatly increased
in DCIS compared to HN (72.35- and 51.88-fold,
respectively) and to PRM (106.24- and 19.06-fold,
respectively), and they are slightly increased in HN com-
pared to PRM (2.0- and 2.52-fold, respectively). Target
prediction analysis identified 13 inverse targets of miR-
182 and four inverse targets of miR-183 (Table 3). We
selected CBX7, DOK4 and NMT2 for miR-182 validation
and EGR1 for miR-183 validation. CBX7 is a chromobox
family protein and a member of the polycomb-repressive
complex 1 that positively regulates E-cadherin expres-
sion through interaction with HDAC2 [46]. DOK4 acts
as an anchor for c-Src kinase, inhibits tyrosine kinase
signaling and can activate MAPK [47,48]. NMT2 is a N-
myristoyltransferase, and myristoylated proteins have
diverse biological functions in signal transduction and
oncogenesis [49]. EGR1 is a Cys2His2- t y p ez i n cf i n g e r
protein that functions as a transcriptional regulator of
target genes required for differentiation and mitogenesis
[50].
To determine whether these genes are authentic tar-
gets of miR-182 and miR-183, we introduced an anti-
sense RNA specifically designed to knock down the
expression of mature miR-182 and miR-183 into MCF7
cells. We observed that from 24 through 72 hours, there
was an upward trend in expression for each of the target
genes, which was significant for three of the four targets
at 72 hours. By 72 hours, the increases in endogenous
expression were 1.23-fold for CBX7, 1.13-fold for DOK4
and 1.34-fold for NMT2. EGR1 was unexpectedly
decreased at 24 hours (0.46-fold), but its expression had
returned to baseline at 48 hours and was increased at
72 hours (1.2-fold) (Figure 2B).
Knockdown of miR-182 induces the expression of E-
cadherin through upregulation of CBX7
It has been suggested that the loss of CBX7 expression
may influence the invasiveness of epithelial cancers by
promoting an epithelial-to-mesenchymal transition
[ 4 6 ] .T h i se f f e c ti sb e l i e v e dt ob ed u et oCBX7’sa b i l i t y
to promote the expression of E-cadherin, a cell
adhesion molecule that plays a role in maintaining
normal epithelial cell morphology by associating with
and inhibiting the repressive action of HDAC2 within
the E-cadherin promoter region. Loss of E-cadherin
expression during neoplastic progression is associated
with several cancers, including breast cancer. In this
study, the expression of CBX7 was reduced 0.44-fold
in the DCIS-HN comparison; however, we did not
observe a significant decrease of E-cadherin in our pre-
invasive clinical samples. It may be that the loss of E-
cadherin expression is more characteristic of the inva-
sive transition or of lobular histology. However, we
asked whether upregulation of CBX7 due to the reduc-
tion of its targeting miRNA (miR-182) would also lead
to upregulation of E-cadherin expression in vitro.W e
found that by 48 hours postknockdown of miR-182,
the protein levels of both CBX7 and E-cadherin were
upregulated by approximately 35% to 40% relative to
control (Figures 3A and 3B).
Discussion
In this study, we identified a set of miRNA that are
expressed in normal breast epithelium and found that
major miRNA expression changes occur at the transi-
tion from normal to DCIS epithelium, thereby defining
a set of putative oncogenic and tumor suppressor
miRNA that are dysregulated at the preinvasive stage of
breast cancer. A greater number of miRNA were
expressed in PRM compared to HN and DCIS, which is
contrary to what we have observed in our gene expres-
sion studies, and we recognize that the high Ct cutoff
values employed could have influenced these results
[15,16]. However, this observation fits with the current
understanding of miRNA regulation of mRNA expres-
sion, given that a greater number of expressed miRNA
would correspond to fewer expressed mRNA.
Twenty of these miRNA have previously been impli-
cated in IBC, and 62% of the miRNA dysregulated in the
HN-DCIS comparison are directionally concordant with
miRNA dysregulated in IBC. This work identifies a role
for these previously implicated miRNA at an early stage
of breast cancer development. For example, we found
that miR-145 expression was underexpressed in the
DCIS-HN comparison. Using an in situ hybridization
approach, Sempere et al. [14] found that miR-145 was
restricted to the myoepithelial/basal cell compartment of
normal mammary ducts and lobules and was reduced or
absent in matching tumor specimens. This finding lends
support to our discovery of decreased miR-145 in DCIS,
because we know that our epithelial samples include
myoepithelial cells.
Although we observed a high concordance rate with
previous reports in IBC, in contrast to the seminal study
by Iorio et al. [13], which examined miRNA expression
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identified as highly overexpressed in breast tumor tis-
sues. However, miR-155 was not differentially expressed
in any of our comparisons. This suggests that either
miR-155 is an invasive, specific miRNA or its expression
is not epithelium-specific, and also that it was detected
because of the heterogeneous cell population presenting
bulk tumor tissue. miR-155 has since been described in
immune cell function, which supports the latter scenario
[51]. Comparison of our data set to others may shed
light on other miRNA whose expression is specific to
either cancer stage or a particular cell type.
The identification of miRNA targets is crucial to the
understanding of their biological role. We hypothesized
that there is a coordinate mechanism of dysregulation
between the abnormal expression of miRNA and target
mRNA in very early breast tumorigenesis. By combin-
ing miRNA and gene expression data and integrating
miRNA target prediction, we obtained a set of candi-
date miRNA:mRNA target pairs. Approximately one-
half of these target pairs were coordinately expressed
and are either false-positive predictions or may in fact
positively regulate the target mRNA, albeit a less well-
understood phenomenon. However, several instances
of miRNA-positive regulation of a target gene have
been described [52-54]. In addition, it has been noted
that two classes of miRNA network motifs, corre-
sponding to positive and negative regulation of a
miRNA and its target, may coexist, and in neuronal
cells miRNA tend to be coexpressed in the same direc-
tion as their target genes [55]. This may in part explain
our observations, although further studies are needed.
Our approach has identified many potentially impor-
tant early-acting, cancer-promoting mRNA targets, and
miRNA dysregulation is a potential mechanism causing
these early mRNA changes. Many of the identified target
genes have known cancer or anticancer activity. For
example, TXNIP (thioredoxin-interacting protein),
EGR1, CBX7, HOXA9 and FOXN3 (checkpoint repressor
1) have tumor suppressor functions and are targeted by
the potentially oncogenic miRNA miR-93, miR-183,
miR-181b, miR-182 and miR-7. Similarly, WWP1, SDC1
(syndecan 1), EZH2, CCND1, ADAM9 and MEMO1
have oncogenic activities and are targeted by the poten-
tially tumor suppressor miRNA miR-195, miR-10b, let-
7c, miR-17 and miR-125b.
Many of these target pairs are likely to be relevant to
cancer in general and breast cancer in particular; how-
ever, we could validate only a subset of these. We found
that with modulation of miR-125b, miR-182 and miR-
183 expression, we obtained results that suggest these
miRNA do regulate the expression of their predicted
target genes. The expression of miR-125b is reduced in
many cancers, including breast cancer [13,56] and
serous ovarian carcinoma [57]. In addition, it has been
established that miR-125b targets ErbB2/Her2, and by
also targeting MEMO1, which interacts with ErbB2/
Her2, miR-125b is regulating two functionally related
genes. miR-182 and miR-183 are clustered at 7q31.2, a
region that is frequently amplified in melanoma [58],
and both miRNA are commonly codysregulated in many
cancers, including prostate, colon and breast cancer
[33,59,60]. In this study, we found that by suppressing
the expression of miR-182 and miR-183 in vitro,t h e
expression of their four predicted targets, CBX7, DOK4,
NMT2 and EGR1, were upregulated. Two of these,
CBX7 and EGR1, have well-described tumor suppressor
functions, and recently DOK4 family members (DOK1,
DOK2,a n dDOK3) were identified as lung tumor sup-
pressors [61]. In addition, the secondary effect of miR-
182 repression resulting in upregulation of E-cadherin
through CBX7, which we have shown, may have impor-
tant implications in reversing epithelial neoplasias to a
more normal state. Furthermore, in future studies, com-
bined modulation of miR-125b, miR-182 and/or miR-
183, as well as other miRNA altered in DCIS, may be
effective in reversing the forward progression to IBC.
Admittedly, our study has several limitations, most
notably the small sample size and the inclusion of only
ER- and PR-positive DCIS. With the use of microdis-
sected, paired breast tissue samples and robust statistical
analysis, we sought to minimize potential biases elicited
by small the sample size. In fact, the many similarities
between our miRNA expression profile of DCIS and
others’ miRNA expression profiling of IBC suggest that
our results are reliable. However, an expansion of this
study to include other histological categories could iden-
tify subtype-specific dysregulated miRNA.
Conclusions
The present study provides the first report of a miRNA
expression profile in normal breast epithelium and the
f i r s ti n t e g r a t e da n a l y s i so fm i R N Aa n dm R N Ae x p r e s -
sion in paired samples of histologically normal and pre-
invasive breast cancer. We have further demonstrated,
by modulating the expression of several miRNA, that
the expression of their predicted target genes is affected.
Taken together, these findings support our hypothesis
that changes in miRNA expression in early breast cancer
may control many of the parallel changes in gene
expression at this stage. This work also implicates the
loss of the tumor suppressor miR-125b and the gain of
the oncogenic miRNA miR-182 and miR-183 as major
contributors to early breast cancer development. Addi-
tionally, this study has revealed novel candidate markers
of preinvasive breast cancer, which could contribute to
the identification of new diagnostic and therapeutic tar-
gets. The miRNA and miRNA:mRNA target pairs
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investigations.
Additional material
Additional file 1: LCM series of representative breast epithelial
lesions. Lesions were obtained from healthy normal (RM), histologically
normal (HN) and paired adjacent ductal carcinoma in situ (DCIS). Lesions
were microdissected from 10-μm-thick consecutive tissue sections. Left-
right: standard hematoxylin and eosin (H&E)-stained “guide slide,” diluted
H&E-stained precapture and postcapture stromal compartments and
captured epithelial compartment. Original magnification, ×40.
Additional file 2: x-y scatter correlation plot of triplicate PRM
samples. The cycle threshold (CT) values for each of the 385 assays from
the three replicate PRM samples are plotted against one another. R
2 =
0.88, 0.91 and 0.90 (mean = 0.90), respectively, and Pearson’s correlation
coefficients were 0.94, 0.96 and 0.95 (mean = 0.95), respectively.
Additional file 3: List of microRNA considered present or absent in each
histological group.
Additional file 4: Expression profiling heatmap of 35 microRNA
(miRNA) differentially expressed between PRM, HN and DCIS.
Hierarchical clustering heatmap representation of 35 miRNA
overexpressed (red) and underexpressed (green) between PRM, HN and
DCIS (P < 0.005, fold change >3), sorted by physical (chromosomal)
position from top to bottom. Black indicates no change in expression.
Brackets indicate the 16 clustered miRNA. Rows, miRNA; columns, profiled
patient samples; shaded boxes, lesion type or replicate sample.
Additional file 5: All genes significantly differentially expressed in paired
HN and DCIS.
Additional file 6: Expression correlation of microRNA and coordinately
expressed predicted targets.
Additional file 7: Enriched gene ontology terms for predicted target
genes.
Additional file 8: Cancer-specific functional annotation and pathway
analysis of predicted target genes.
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CBX7: chromobox homolog 7; DCIS: ductal carcinoma in situ; DOK4: docking
protein 4; EGR1: early growth response 1; HN: histologically normal; MEMO1:
mediator of ErbB2-driven cell motility; miRNA: microRNA; mRNA: messenger
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